Literature DB >> 8926241

Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury.

J F Lewis1, J Goffin, P Yue, L A McCaig, D Bjarneson, R A Veldhuizen.   

Abstract

Two exogenous surfactant preparations [Survanta and bovine lipid extract surfactant (BLES)] were evaluated in saline lavage-injured adult sheep with two different delivery methods (instillation vs. aerosolization). Instilled BLES resulted in the greatest improvement in lung function, followed by aerosolized Survanta and then instilled Survanta. Aerosolized BLES was ineffective. Total surfactant recovery and distribution patterns were similar for Survanta and BLES for each delivery method tested. There were significant differences, however, in the proportion of surfactant recovered in the alveolar wash relative to the lung tissue between the groups at killing. Moreover, the ratio of poorly functioning small surfactant aggregates to superior functioning large aggregates isolated from alveolar wash samples correlated with the physiological responses. The calculated contribution of secreted endogenous surfactant to the total alveolar phospholipid pool at killing was significantly greater for the aerosolized Survanta group compared with the aerosolized BLES group. This finding suggested that there were differences in the interaction of the exogenous surfactants and their alveolar environments. We conclude that the response to exogenous surfactant in acute lung injury depends not only on the preparation used but also on how the surfactants are delivered to the injured lung.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8926241     DOI: 10.1152/jappl.1996.80.4.1156

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  8 in total

Review 1.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

Review 2.  [Value of surfactant replacement therapy in the treatment of acute respiratory distress syndrome].

Authors:  S Lauer; L G Fischer; H D Stubbe; H Van Aken; M Westphal
Journal:  Anaesthesist       Date:  2006-04       Impact factor: 1.041

Review 3.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

Review 4.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

Review 5.  Surfactant administration in neonates: A review of delivery methods.

Authors:  Nina Nouraeyan; Alicia Lambrinakos-Raymond; Marisa Leone; Guilherme Sant'Anna
Journal:  Can J Respir Ther       Date:  2014

Review 6.  Exogenous surfactant therapy in 2013: what is next? Who, when and how should we treat newborn infants in the future?

Authors:  Emmanuel Lopez; Géraldine Gascoin; Cyril Flamant; Mona Merhi; Pierre Tourneux; Olivier Baud
Journal:  BMC Pediatr       Date:  2013-10-10       Impact factor: 2.125

7.  The effects of exogenous surfactant administration on ventilation-induced inflammation in mouse models of lung injury.

Authors:  Valeria Puntorieri; Josh Qua Hiansen; Lynda A McCaig; Li-Juan Yao; Ruud A W Veldhuizen; James F Lewis
Journal:  BMC Pulm Med       Date:  2013-11-20       Impact factor: 3.317

8.  Effective in vivo treatment of acute lung injury with helical, amphipathic peptoid mimics of pulmonary surfactant proteins.

Authors:  Ann M Czyzewski; Lynda M McCaig; Michelle T Dohm; Lauren A Broering; Li-Juan Yao; Nathan J Brown; Maruti K Didwania; Jennifer S Lin; Jim F Lewis; Ruud Veldhuizen; Annelise E Barron
Journal:  Sci Rep       Date:  2018-05-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.